Dermatology Daily Report: 01/22/2024

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled study (SPROUT, NCT03701763) investigated the effect of apremilast in 245 pediatric patients aged 6-17 years with moderate-to-severe plaque psoriasis. Significantly more patients achieved sPGA response and ≥75% reduction in PASI with apremilast than placebo, regardless of baseline age, weight, or disease severity (1). Of 245 patients randomized (apremilast: 163; placebo: 82), 221 (90%) completed the double-blind phase.

Reference

Fiorillo L, Becker E, de Lucas R, Belloni-Fortina A, Armesto S, Elewski B, Maes P, Oberoi RK, Paris M, Zhang W, Zhang Z, Arkin L. EFFICACY AND SAFETY OF APREMILAST IN PEDIATRIC PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS: 16-WEEK RESULTS FROM SPROUT, A RANDOMIZED CONTROLLED TRIAL. J Am Acad Dermatol. 2024 Jan 22:S0190-9622(24)00108-7. doi: 10.1016/j.jaad.2023.11.068. Epub ahead of print. PMID: 38266683.